Med. praxi. 2019;16(1):23-26 | DOI: 10.36290/med.2019.004

Treating arterial hypertension in patients with metabolic syndrome

doc. MUDr. Filip Málek, Ph.D., MBA
Ambulance srdečního selhání a hypertenze, Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

Metabolic syndrome is defined by the presence of several factors that share a common pathophysiological basis. The presence of metabolic syndrome is associated with a high risk of fatal cardiovascular and cerebrovascular events. The prevalence of metabolic syndrome is high. The management of metabolic syndrome is always comprehensive. The treatment of arterial hypertension as part of metabolic syndrome has its specific features. Metabolically neutral and metabolically positive drugs are preferred, particularly those of the renin-angiotensin system inhibitor group. A combination with statins is beneficial for their potential to reduce the risk of cardiovascular events. A modern treatment of hypertension and metabolic syndrome utilizes the option of fixed drug combinations that increase patient adherence to therapy.

Keywords: arterial hypertension, metabolic syndrome, cardiovascular risk, treatment

Published: February 25, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Treating arterial hypertension in patients with metabolic syndrome. Med. praxi. 2019;16(1):23-26. doi: 10.36290/med.2019.004.
Download citation

References

  1. Svobodová Š, Topolčan O. Metabolický syndrom, predikce a prevence. Interní Med. 2012; 14(11): 412-414.
  2. Cífková R, Bruthans J, Adámková V, et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post-MONICA. Cor Vasa 2011; 53: 220-229. Go to original source...
  3. Souček M, Řiháček I. Kombinační léčba v rámci metabolického syndromu. Interní Med. 2015; 17(2): 64-68.
  4. Assmann G, Schulte H. The Prospective Cardio-vascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-1724. Go to original source... Go to PubMed...
  5. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. Go to original source... Go to PubMed...
  6. Souček M, Kára T, et al. Klinická patofyziologie hypertenze: genetické pozadí a další obecné mechanismy vzniku hypertenze a diabetes mellitus. Praha, Grada Publishing, 2002.
  7. Neve B, Fruchart JC, Staels B. Role of the per-oxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000; 60: 1245-1250. Go to original source...
  8. Souček M, Kára T, et al. Klinická patofyziologie hypertenze: význam ANS v časných stádiích hypertenze. Praha, Grada Publishing, 2002.
  9. Widimský J, Filipovský J, Ceral J, et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze a kardiovaskulární prevence 2018; 7(Suppl.): 1-19.
  10. Gradman AH, Basile JN, Carter BL, Barkis GL. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4(2): 90-98. Go to original source... Go to PubMed...
  11. Patel A and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcome in patients with type 2 diabetes mellitus (the ADVANCE trial). The Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
  12. Poulter NR, Peters R, Fletcher AE, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source...
  13. Jamerson KA, Weber MA, Bakris GL, et al. For the ACCOMPLISH Trial Investigators. Benazepril plus Amlodipin or Hydrochlorothiazide for Hypertension in High Risk Patients. N Engl J Med 2008; 359: 2417-2428. Go to original source...
  14. Williams B, Mancia G, Spiering W, et al. For The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Doporučení pro diagnostiku a léčbu arteriální hypertenze ESC/ESH 2018. European Heart Journal 2018; 39(33): 3021-3104. Go to original source...
  15. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes trial: Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.